CRISPR/Cas9 technology generated an AGG to CAA change at residues 310-312 resulting in an arginine to glutamine substitution at amino acid 104 (R104Q). This is a mutation seen in progressive myoclonus epilepsy. (J:321396)
查看原文 参与反馈
CRISPR/Cas9 technology generated an AGG to CAA change at residues 310-312 resulting in an arginine to glutamine substitution at amino acid 104 (R104Q). This is a mutation seen in progressive myoclonus epilepsy. (J:321396)